Cited by 105Bone Metabolism and DiseasesFibroblast Growth Factor ResearchThyroid Disorders and Treatments

Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone

Open access
Stevens, David A., Harvey, Clare B., Scott, Anthea J., O’Shea, Patrick J., Barnard, Joanna C., Williams, Allan J., Brady, Gerard, Samarut, Jacques +2 more·2003·Molecular Endocrinology

Abstract

Thyroid hormone (T3) and the T3 receptor (TR) alpha gene are essential for bone development whereas adult hyperthyroidism increases the risk of osteoporotic fracture. We isolated fibroblast growth factor receptor-1 (FGFR1) as a T3-target gene in osteoblasts by subtraction hybridization. FGFR1 mRNA was induced 2- to 3-fold in osteoblasts treated with T3 for 6-48 h, and FGFR1 protein was stimulated 2- to 4-fold. Induction of FGFR1 was independent of mRNA half-life and abolished by actinomycin D and cycloheximide, indicating the involvement of an intermediary protein. Fibroblast growth factor 2 (FGF2) stimulated MAPK in osteoblasts, and pretreatment with T3 for 6 h induced a more rapid response to FGF that was increased in magnitude by 2- to 3-fold. Similarly, T3 enhanced FGF2-activated autophosphorylation of FGFR1, but did not modify FGF2-induced phosphorylation of the docking protein FRS2. These effects were abolished by the FGFR-selective inhibitors PD166866 and PD161570. In situ hybridization analyses of TRalpha-knockout mice, which have impaired ossification and skeletal mineralization, revealed reduced FGFR1 mRNA expression in osteoblasts and osteocytes, whereas T3 failed to stimulate FGFR1 mRNA or enhance FGF2-activated MAPK signaling in TRalpha-null osteoblasts. These findings implicate FGFR1 signaling in T3-dependent bone development and the pathogenesis of skeletal disorders resulting from thyroid disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/me.2003-0137

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Stevens, D. A., Harvey, C. B., Scott, A. J., O’Shea, P. J., Barnard, J. C., Williams, A. J., Brady, G., Samarut, J., Chassande, O., & Williams, G. R.
Affiliations
  • Hammersmith Hospital (GB)
  • Imperial College London (GB)
  • University of Manchester (GB)
  • École Normale Supérieure de Lyon (FR)
Corresponding author
Williams, Graham R.
Venue
Molecular Endocrinology
Published
2003-09
Volume
17
Issue
9
Pages
1751-1766
ISSN
  • 0888-8809 (ISSN-L)
  • 1944-9917
OpenAlex
W1964583412
Cited by
105
References
57
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 4 · 2019: 7 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 8 · 2013: 7 · 2012: 8
FWCI
1.49
Type
journal article
Language
en
Open access
Locations
  • Molecular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Wellcome Trust (050570)
  • Nuffield Foundation
  • Medical Research Council (G9803002)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
thyroid hormones, FGFR1, FGFR1 signaling, FGF2, MAPK signaling, osteoblasts, osteocytes, skeletal development, thyroid dysfunction, osteoporosis, skeletal mineralization, FRS2
MeSH terms
Animals, Bone and Bones, Osteoblasts, Phosphorylation, Phosphotransferases, Pyrimidines, Thyroid Gland, Triiodothyronine, Urea, Signal Transduction, Fibroblast Growth Factor 2, Receptors, Fibroblast Growth Factor, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Mice, Receptor, Fibroblast Growth Factor, Type 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review